Evidence map›Paper›PMID 40711648›Full record

ArticleMolecular biology reports2025

The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients.

Maya Bouafia, Mohamed El Amine Smaali, Souheila Zemmouchi, Ali Boumegoura, Selwa Bellara, Ayomide Victor Atoki, Raid Serrar, Khalid Bouhedjar, Mohammed Messaoudi, Noureddine Abadi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maya BouafiaLaboratory of Molecular and Cellular Biology, University Brothers Mentouri Constantine 1, Constantine, Algeria.
Mohamed El Amine SmaaliBiotechnology Research Center Constantine, El Khroub, Algeria.
Souheila ZemmouchiDepartment of Nephrology, Specialized Hospital Establishments Daksi, Constantine, Algeria.
Ali BoumegouraBiotechnology Research Center Constantine, El Khroub, Algeria.
Selwa BellaraBiotechnology Research Center Constantine, El Khroub, Algeria.
Ayomide Victor AtokiDepartment of Biochemistry, Kampala International University, Ishaka, Uganda. messaoudi2006@yahoo.fr.
Raid SerrarDepartment of Applied Biology, University Frères Mentouri Constantine 1, Constantine, Algeria.
Khalid BouhedjarBiotechnology Research Center Constantine, El Khroub, Algeria.
Mohammed MessaoudiNuclear Research Centre of Birine, Ain Oussera, Djelfa, 17200, Algeria.
Noureddine AbadiLaboratory of Biology and Molecular Genetics, University Salah Boubnider Constantine 3, Constantine, Algeria.
Mohamed Habib BelmahiDepartment of Pharmacy, Laboratory of Toxicology, University Constantine 3, Constantine, Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCyclosporine (CsA) is a calcineurin inhibitor (CNI) commonly prescribed after organ transplantation to reduce the risk of graft rejection and prolong both graft and patient survival. However, its clinical use is often limited by a narrow therapeutic index and highly variable, unpredictable pharmacokinetics. Consequently, close therapeutic monitoring is essential to ensure effective immunosuppression. Genetic polymorphisms in cytochrome P450 3 A (CYP3A) enzymes and the multidrug resistance gene 1 (ABCB1) may influence CsA dose requirements and blood concentrations in renal transplant recipients. METHODS AND

resultsThis study aimed to evaluate the impact of selected single nucleotide polymorphisms (SNPs) in CYP3A4, CYP3A5, and ABCB1 genes in a cohort of Algerian renal transplant patients. Fifty stable kidney transplant recipients were enrolled. SNPs of CYP3A4, CYP3A5 and ABCB1 genes were detected with direct sequencing and associations between genotypes and CsA dose requirements, trough concentrations (C₀), 2 h post dose concentration (C

conclusionsIn conclusion, the CYP3A5 A6986G (*3/*3) polymorphism is significantly associated with higher CsA trough levels and dose-adjusted concentrations, as well as increased cholesterol levels in stable renal transplant recipients even with similar doses. Conversely, variability in CsA pharmacokinetics does not appear to be significantly influenced by ABCB1 3435 C > T polymorphisms.

Indexed as

CyclosporineCytochrome P-450 CYP3AKidney TransplantationPolymorphism, Single NucleotideAdultAlgeriaATP Binding Cassette Transporter, Subfamily BFemaleGenotypeHumansImmunosuppressive AgentsMaleMiddle AgedTransplant RecipientsABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BCyclosporineCYP3A4 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP3AImmunosuppressive AgentsABCB1CyclosporineCYP3APersonalized therapyPharmacokineticsPolymorphismRenal transplant recipients

Identifiers

PMID40711648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.